Immutep Ltd Call For Topline Data From The Phase IIb AIPAC Study In HER2-negative/HR+ Metastatic Breast Cancer Transcript
Greetings, and welcome to Immutep's call for top line data from the Phase IIb AIPAC study and HER2-negative HR metastatic breast cancer conference call. (Operator Instructions) Please note, this conference is being recorded.
I will now turn the conference over to your host, Tim McCarthy, Managing Director of LifeSci Advisors. Please go ahead.
(technical difficulty)
on the company's AIPAC study of its lead product candidate, eftilagimod alpha. I will be your moderator today. And at the end of the presentation, I will ask questions we received via e-mail prior to this call.
I would now like to hand over the call to Marc Voigt, Immutep's CEO, to start the presentation. Marc?
Yes. Thank you very much, Tim. And thank you all, and welcome, everyone. We are pleased to have you to join us on the call today. Especially also given the COVID
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |